Go Pro

Thermo Fisher Scientific (TMO) Competitors

Thermo Fisher Scientific logo
$681.04 +2.44 (+0.36%)
Closing price 03:59 PM Eastern
Extended Trading
$680.73 -0.31 (-0.05%)
As of 04:21 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

TMO vs. ILMN, MEDP, A, AMN, and BIO

Should you buy Thermo Fisher Scientific stock or one of its competitors? Thermo Fisher Scientific's main competitors and comparable companies include Illumina (ILMN), Medpace (MEDP), Agilent Technologies (A), AMN Healthcare Services (AMN), and Bio-Rad Laboratories (BIO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Thermo Fisher Scientific compare to Illumina?

Illumina (NASDAQ:ILMN) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, risk, institutional ownership, profitability, analyst recommendations and dividends.

Thermo Fisher Scientific has higher revenue and earnings than Illumina. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Illumina$4.34B9.46$850M$5.3650.75
Thermo Fisher Scientific$44.56B5.65$6.70B$18.5936.63

Illumina has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market.

Illumina presently has a consensus price target of $209.75, indicating a potential downside of 22.89%. Thermo Fisher Scientific has a consensus price target of $628.78, indicating a potential downside of 7.67%. Given Thermo Fisher Scientific's stronger consensus rating and higher possible upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Illumina.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Illumina
2 Sell rating(s)
6 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.44
Thermo Fisher Scientific
2 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.77

Illumina has a net margin of 18.36% compared to Thermo Fisher Scientific's net margin of 15.04%. Illumina's return on equity of 29.84% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Illumina18.36% 29.84% 12.17%
Thermo Fisher Scientific 15.04%17.09%8.12%

89.4% of Illumina shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 2.9% of Illumina shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Thermo Fisher Scientific had 6 more articles in the media than Illumina. MarketBeat recorded 19 mentions for Thermo Fisher Scientific and 13 mentions for Illumina. Thermo Fisher Scientific's average media sentiment score of 1.01 beat Illumina's score of 0.61 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Illumina
5 Very Positive mention(s)
0 Positive mention(s)
6 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
15 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Thermo Fisher Scientific beats Illumina on 9 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Medpace?

Thermo Fisher Scientific (NYSE:TMO) and Medpace (NASDAQ:MEDP) are both large-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Thermo Fisher Scientific presently has a consensus price target of $628.78, indicating a potential downside of 7.67%. Medpace has a consensus price target of $595.20, indicating a potential downside of 4.33%. Given Medpace's higher probable upside, analysts plainly believe Medpace is more favorable than Thermo Fisher Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Thermo Fisher Scientific
2 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.77
Medpace
0 Sell rating(s)
9 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.25

Thermo Fisher Scientific has higher revenue and earnings than Medpace. Medpace is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Thermo Fisher Scientific$44.56B5.65$6.70B$18.5936.63
Medpace$2.53B6.86$451.12M$17.0636.47

Medpace has a net margin of 17.67% compared to Thermo Fisher Scientific's net margin of 15.04%. Medpace's return on equity of 110.15% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Thermo Fisher Scientific15.04% 17.09% 8.12%
Medpace 17.67%110.15%24.84%

Thermo Fisher Scientific has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market. Comparatively, Medpace has a beta of 1.15, suggesting that its stock price is 15% more volatile than the broader market.

89.2% of Thermo Fisher Scientific shares are owned by institutional investors. Comparatively, 78.0% of Medpace shares are owned by institutional investors. 0.3% of Thermo Fisher Scientific shares are owned by company insiders. Comparatively, 20.5% of Medpace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Medpace had 1 more articles in the media than Thermo Fisher Scientific. MarketBeat recorded 20 mentions for Medpace and 19 mentions for Thermo Fisher Scientific. Thermo Fisher Scientific's average media sentiment score of 1.01 beat Medpace's score of 0.57 indicating that Thermo Fisher Scientific is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Thermo Fisher Scientific
15 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Medpace
9 Very Positive mention(s)
2 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

Thermo Fisher Scientific beats Medpace on 9 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Agilent Technologies?

Agilent Technologies (NYSE:A) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

In the previous week, Thermo Fisher Scientific had 2 more articles in the media than Agilent Technologies. MarketBeat recorded 19 mentions for Thermo Fisher Scientific and 17 mentions for Agilent Technologies. Thermo Fisher Scientific's average media sentiment score of 1.01 beat Agilent Technologies' score of 0.58 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Agilent Technologies
7 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
15 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Agilent Technologies currently has a consensus price target of $170.33, suggesting a potential downside of 2.72%. Thermo Fisher Scientific has a consensus price target of $628.78, suggesting a potential downside of 7.67%. Given Agilent Technologies' stronger consensus rating and higher probable upside, equities analysts clearly believe Agilent Technologies is more favorable than Thermo Fisher Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agilent Technologies
0 Sell rating(s)
5 Hold rating(s)
14 Buy rating(s)
1 Strong Buy rating(s)
2.80
Thermo Fisher Scientific
2 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.77

Thermo Fisher Scientific has higher revenue and earnings than Agilent Technologies. Agilent Technologies is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agilent Technologies$6.95B7.11$1.30B$5.0834.47
Thermo Fisher Scientific$44.56B5.65$6.70B$18.5936.63

89.2% of Thermo Fisher Scientific shares are held by institutional investors. 0.3% of Thermo Fisher Scientific shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Agilent Technologies pays an annual dividend of $1.02 per share and has a dividend yield of 0.6%. Thermo Fisher Scientific pays an annual dividend of $1.88 per share and has a dividend yield of 0.3%. Agilent Technologies pays out 20.1% of its earnings in the form of a dividend. Thermo Fisher Scientific pays out 10.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Agilent Technologies has raised its dividend for 9 consecutive years and Thermo Fisher Scientific has raised its dividend for 8 consecutive years. Agilent Technologies is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Agilent Technologies has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.85, meaning that its stock price is 15% less volatile than the broader market.

Agilent Technologies has a net margin of 19.53% compared to Thermo Fisher Scientific's net margin of 15.04%. Agilent Technologies' return on equity of 24.45% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
Agilent Technologies19.53% 24.45% 13.09%
Thermo Fisher Scientific 15.04%17.09%8.12%

Summary

Thermo Fisher Scientific beats Agilent Technologies on 11 of the 20 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Thermo Fisher Scientific (NYSE:TMO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

AMN Healthcare Services has a beta of 0.38, suggesting that its stock price is 62% less volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.85, suggesting that its stock price is 15% less volatile than the broader market.

Thermo Fisher Scientific has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Thermo Fisher Scientific, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.73B0.50-$95.70M$2.6813.04
Thermo Fisher Scientific$44.56B5.65$6.70B$18.5936.63

AMN Healthcare Services currently has a consensus price target of $36.00, indicating a potential upside of 2.98%. Thermo Fisher Scientific has a consensus price target of $628.78, indicating a potential downside of 7.67%. Given AMN Healthcare Services' higher probable upside, equities research analysts clearly believe AMN Healthcare Services is more favorable than Thermo Fisher Scientific.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
0 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.50
Thermo Fisher Scientific
2 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.77

In the previous week, Thermo Fisher Scientific had 14 more articles in the media than AMN Healthcare Services. MarketBeat recorded 19 mentions for Thermo Fisher Scientific and 5 mentions for AMN Healthcare Services. Thermo Fisher Scientific's average media sentiment score of 1.01 beat AMN Healthcare Services' score of 0.64 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
2 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Thermo Fisher Scientific
15 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Thermo Fisher Scientific has a net margin of 15.04% compared to AMN Healthcare Services' net margin of 3.06%. AMN Healthcare Services' return on equity of 19.92% beat Thermo Fisher Scientific's return on equity.

Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services3.06% 19.92% 5.93%
Thermo Fisher Scientific 15.04%17.09%8.12%

Summary

Thermo Fisher Scientific beats AMN Healthcare Services on 13 of the 17 factors compared between the two stocks.

How does Thermo Fisher Scientific compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO) and Thermo Fisher Scientific (NYSE:TMO) are both large-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Thermo Fisher Scientific has higher revenue and earnings than Bio-Rad Laboratories. Thermo Fisher Scientific is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bio-Rad Laboratories$2.58B3.93$759.90M$8.2546.05
Thermo Fisher Scientific$44.56B5.65$6.70B$18.5936.63

Bio-Rad Laboratories currently has a consensus price target of $343.33, suggesting a potential downside of 9.63%. Thermo Fisher Scientific has a consensus price target of $628.78, suggesting a potential downside of 7.67%. Given Thermo Fisher Scientific's stronger consensus rating and higher probable upside, analysts plainly believe Thermo Fisher Scientific is more favorable than Bio-Rad Laboratories.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bio-Rad Laboratories
0 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.20
Thermo Fisher Scientific
2 Sell rating(s)
4 Hold rating(s)
18 Buy rating(s)
2 Strong Buy rating(s)
2.77

In the previous week, Thermo Fisher Scientific had 15 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 19 mentions for Thermo Fisher Scientific and 4 mentions for Bio-Rad Laboratories. Thermo Fisher Scientific's average media sentiment score of 1.01 beat Bio-Rad Laboratories' score of 0.41 indicating that Thermo Fisher Scientific is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Bio-Rad Laboratories
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Thermo Fisher Scientific
15 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Bio-Rad Laboratories has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, Thermo Fisher Scientific has a beta of 0.85, indicating that its share price is 15% less volatile than the broader market.

Thermo Fisher Scientific has a net margin of 15.04% compared to Bio-Rad Laboratories' net margin of 8.59%. Thermo Fisher Scientific's return on equity of 17.09% beat Bio-Rad Laboratories' return on equity.

Company Net Margins Return on Equity Return on Assets
Bio-Rad Laboratories8.59% 3.54% 2.48%
Thermo Fisher Scientific 15.04%17.09%8.12%

65.2% of Bio-Rad Laboratories shares are held by institutional investors. Comparatively, 89.2% of Thermo Fisher Scientific shares are held by institutional investors. 30.3% of Bio-Rad Laboratories shares are held by company insiders. Comparatively, 0.3% of Thermo Fisher Scientific shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Thermo Fisher Scientific beats Bio-Rad Laboratories on 14 of the 17 factors compared between the two stocks.

Get Thermo Fisher Scientific News Delivered to You Automatically

Sign up to receive the latest news and ratings for TMO and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

TMO vs. The Competition

MetricThermo Fisher ScientificLife Sciences Tools & Services IndustryHealthcare SectorNYSE Exchange
Market Cap$251.81B$10.99B$7.26B$22.74B
Dividend Yield0.28%1.45%2.52%3.68%
P/E Ratio36.6375.39274.9827.67
Price / Sales5.65109.08606.8520.20
Price / Cash22.2027.5528.0219.27
Price / Book4.796.3510.504.64
Net Income$6.70B$57.48B$3.50B$1.07B
7 Day Performance3.29%2.89%-3.01%-2.80%
1 Month Performance9.51%6.16%-4.15%-5.85%
1 Year Performance47.43%42.59%13.25%5.75%

Thermo Fisher Scientific Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
TMO
Thermo Fisher Scientific
4.3757 of 5 stars
$681.04
+0.4%
$628.78
-7.7%
+46.0%$251.81B$44.56B36.63125,000
ILMN
Illumina
1.9473 of 5 stars
$238.82
-0.3%
$199.13
-16.6%
+196.5%$36.06B$4.49B44.568,650
MEDP
Medpace
2.3455 of 5 stars
$624.20
+1.9%
$595.20
-4.6%
+24.0%$17.42B$2.53B36.596,200
A
Agilent Technologies
4.1793 of 5 stars
$162.06
+3.6%
$170.33
+5.1%
+42.1%$45.69B$7.37B31.9018,100
AMN
AMN Healthcare Services
1.415 of 5 stars
$34.15
-0.3%
$36.00
+5.4%
+81.5%$1.32B$3.43B12.742,664

Related Companies and Tools


This page (NYSE:TMO) was last updated on 9/29/2026 by MarketBeat.com Staff.
From Our Partners